Skip to content

Study · Observational study · 2025

6 results

Dosing Patterns of Dulaglutide and Semaglutide in Patients with Type 2 Diabetes Mellitus in France and Italy: A Retrospective Cohort Study.

Khare S, Osumili B, Debackere N, Keapoletswe K, Falato S, Raoul T, Coles B

Advances in therapy2 Nov 2024Cited by 1 (Europe PMC)

PMID39487881 (opens in a new tab)PMCIDPMC11782337 (opens in a new tab)DOI10.1007/s12325-024-03002-9 (opens in a new tab)PepBankPUB-39487881
Read at sourcePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanObservational studyOther

    In dulaglutide-naïve patients, 62% in France and 49% in Italy started at 1.5 mg.

    In plain wordsAmong new dulaglutide users, 62% in France and 49% in Italy started at 1.5 mg.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableStarting dose in France and Italy
    Study

    n: not reported in source

    Outcome group
    Patterns of use · Pharmacology
    Studied dose
    Dose not stated

    Measurements

    Starting dose proportion
    62%
    France, 1.5 mg
    Starting dose proportion
    49%
    Italy, 1.5 mg

    Source sentences

    Summary
    Most dulaglutide-naïve patients in France (62%) and approximately half in Italy (49%) started on 1.5 mg and remained on this dose for up to 12 months (France: 66% cohort 1, 88% cohort 2; Italy: 73% cohort 1, 87% cohort 2).
    2 context sentences
    Summary · context
    IQVIA Longitudinal Prescription Data identified adults with T2DM prescribed dulaglutide or semaglutide between August 1, 2020 and December 31, 2022.
    Summary · context
    Cohort 1 (incident) and cohort 2 (prevalent) users were followed for 12 months.
  2. 02HumanObservational studyOther

    Patients in France and Italy commonly remained on dulaglutide 1.5 mg for up to 12 months.

    In plain wordsPatients in France and Italy commonly remained on dulaglutide 1.5 mg for up to 12 months.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableDose maintenance
    Study

    n: not reported in source

    Outcome group
    Patterns of use · Pharmacology
    Studied dose
    Dose not stated

    Measurements

    Dose maintenance
    66%
    France cohort 1
    Dose maintenance
    88%
    France cohort 2
    Dose maintenance
    73%
    Italy cohort 1
    Dose maintenance
    87%
    Italy cohort 2

    Source sentences

    Summary
    Most dulaglutide-naïve patients in France (62%) and approximately half in Italy (49%) started on 1.5 mg and remained on this dose for up to 12 months (France: 66% cohort 1, 88% cohort 2; Italy: 73% cohort 1, 87% cohort 2).
    2 context sentences
    Summary · context
    IQVIA Longitudinal Prescription Data identified adults with T2DM prescribed dulaglutide or semaglutide between August 1, 2020 and December 31, 2022.
    Summary · context
    Cohort 1 (incident) and cohort 2 (prevalent) users were followed for 12 months.
  3. 03HumanObservational studyOther

    In incident semaglutide users, 78% in France and 61% in Italy started subcutaneous treatment at 0.25 mg.

    In plain wordsAmong new semaglutide users, 78% in France and 61% in Italy started injections at 0.25 mg.

    Peptide
    Semaglutide
    Outcome
    Not applicableSubcutaneous starting dose
    Study

    n: not reported in source

    Outcome group
    Patterns of use · Pharmacology
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Measurements

    Starting dose proportion
    78%
    France, 0.25 mg
    Starting dose proportion
    61%
    Italy, 0.25 mg

    Source sentences

    Summary
    In cohort 1, s.c. semaglutide users mostly started on 0.25 mg (France, 78%; Italy, 61%).
    2 context sentences
    Summary · context
    IQVIA Longitudinal Prescription Data identified adults with T2DM prescribed dulaglutide or semaglutide between August 1, 2020 and December 31, 2022.
    Summary · context
    Cohort 1 (incident) and cohort 2 (prevalent) users were followed for 12 months.
  4. 04HumanObservational studyOther

    At 12 months, semaglutide 1.0 mg predominated except among incident users in Italy, where 0.5 mg predominated.

    In plain wordsAt 12 months, semaglutide 1.0 mg predominated, except among new users in Italy, where 0.5 mg predominated.

    Peptide
    Semaglutide
    Outcome
    Not applicableSubcutaneous dose at follow-up
    Study

    n: not reported in source

    Outcome group
    Patterns of use · Pharmacology
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Measurements

    Dose proportion
    58%
    France cohort 1, 1.0 mg
    Dose proportion
    75%
    France cohort 2, 1.0 mg
    Dose proportion
    59%
    Italy cohort 2, 1.0 mg
    Dose proportion
    57%
    Italy cohort 1, 0.5 mg

    Source sentences

    Summary
    At 12 months, s.c. semaglutide 1.0 mg was most prescribed (France: 58% cohort 1, 75% cohort 2; Italy: 59% cohort 2), with cohort 1 in Italy mostly receiving 0.5 mg (57%).
    2 context sentences
    Summary · context
    IQVIA Longitudinal Prescription Data identified adults with T2DM prescribed dulaglutide or semaglutide between August 1, 2020 and December 31, 2022.
    Summary · context
    Cohort 1 (incident) and cohort 2 (prevalent) users were followed for 12 months.
  5. 05HumanObservational studyOther

    In Italy, most oral semaglutide users started at 3.0 mg.

    In plain wordsIn Italy, most oral semaglutide users started at 3.0 mg.

    Peptide
    Semaglutide
    Outcome
    Not applicableOral starting dose
    Study

    n: not reported in source

    Outcome group
    Patterns of use · Pharmacology
    Studied dose
    Dose not stated · oralAs given in this study (human).

    Measurements

    Starting dose proportion
    78%
    cohort 1, 3.0 mg
    Starting dose proportion
    68%
    cohort 2, 3.0 mg

    Source sentences

    Summary
    Most oral semaglutide users in Italy started on 3.0 mg (78% cohort 1; 68% cohort 2), which was increased to 7.0 mg (62% cohort 1) and 14.0 mg (48% cohort 2) at 12 months.
    2 context sentences
    Summary · context
    IQVIA Longitudinal Prescription Data identified adults with T2DM prescribed dulaglutide or semaglutide between August 1, 2020 and December 31, 2022.
    Summary · context
    Cohort 1 (incident) and cohort 2 (prevalent) users were followed for 12 months.
  6. 06HumanObservational studyOther

    At 12 months in Italy, oral semaglutide increased to 7.0 mg in 62% of incident users and 14.0 mg in 48% of prevalent users.

    In plain wordsAt 12 months in Italy, 62% of new oral semaglutide users received 7.0 mg, and 48% of prevalent users received 14.0 mg.

    Peptide
    Semaglutide
    Outcome
    Not applicableOral dose at follow-up
    Study

    n: not reported in source

    Outcome group
    Patterns of use · Pharmacology
    Studied dose
    Dose not stated · oralAs given in this study (human).

    Measurements

    Dose proportion
    62%
    cohort 1, 7.0 mg
    Dose proportion
    48%
    cohort 2, 14.0 mg

    Source sentences

    Summary
    Most oral semaglutide users in Italy started on 3.0 mg (78% cohort 1; 68% cohort 2), which was increased to 7.0 mg (62% cohort 1) and 14.0 mg (48% cohort 2) at 12 months.
    2 context sentences
    Summary · context
    IQVIA Longitudinal Prescription Data identified adults with T2DM prescribed dulaglutide or semaglutide between August 1, 2020 and December 31, 2022.
    Summary · context
    Cohort 1 (incident) and cohort 2 (prevalent) users were followed for 12 months.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 2

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.